The Chemotherapy+ Foundation shared on LinkedIn:
Thanks to everyone at Chemotherapy+ Foundation for the work you do, and for this honor.”
“‘If you stick with it, ultimately the science will triumph.’ – Matthew Rabinowitz
At our 2026 Innovation Gala, we proudly presented Natera with the inaugural Oncology Vision Award, recognizing its pioneering contributions to precision medicine, genetic testing, and the advancement of cancer diagnostics.
The award was accepted by Matthew Rabinowitz, Co-Founder and Executive Chairman of Natera, who delivered a powerful message on the importance of perseverance, scientific integrity, and an unwavering belief in the potential of research to drive meaningful change.
Reflecting on the challenges of advancing scientific innovation, he emphasized that progress requires more than groundbreaking data. It demands persistence, conviction, and faith in both science and humanity.
His remarks reflect the very principles that guide our mission at The Chemotherapy+ Foundation: championing scientific discovery, supporting the next generation of oncology innovators, and helping accelerate advancements that can transform the future of cancer care.
We congratulate Matthew and the entire Natera team on this well-deserved recognition and thank them for their continued commitment to advancing oncology innovation.”
Natera added:
“Beautifully said, we couldn’t agree more with these remarks from our Co-Founder and Executive Chairman Matthew Rabinowitz as he received the Oncology Vision Award during The Chemotherapy+ Foundation 2026 Innovation Gala.”
You can also read:
